temozolomide has been researched along with entrectinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, KL; Jia, Y; Li, P; Qiao, Y; Zhang, MM | 1 |
| Brodeur, GM; Cam, N; Croucher, JL; Golden, RL; Guan, P; Hornby, Z; Iyer, R; Kolla, V; Li, G; MacFarland, SP; Naraparaju, K; Wehrmann, L; Wei, G | 1 |
2 other study(ies) available for temozolomide and entrectinib
| Article | Year |
|---|---|
New Protocol-Guided Exploitation of a Lysosomal Sulfatase Inhibitor to Suppress Cell Growth in Glioblastoma Multiforme.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Fluorescent Dyes; Glioblastoma; Glucosides; Humans; Lysosomes; Naphthalimides; Prognosis; Sulbactam; Sulfatases | 2021 |
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Humans; Indazoles; Irinotecan; Membrane Glycoproteins; Mice, Nude; Neuroblastoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Temozolomide; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |